CY1124364T1 - Μεθοδοι για την ανιχνευση aav - Google Patents

Μεθοδοι για την ανιχνευση aav

Info

Publication number
CY1124364T1
CY1124364T1 CY20211100262T CY211100262T CY1124364T1 CY 1124364 T1 CY1124364 T1 CY 1124364T1 CY 20211100262 T CY20211100262 T CY 20211100262T CY 211100262 T CY211100262 T CY 211100262T CY 1124364 T1 CY1124364 T1 CY 1124364T1
Authority
CY
Cyprus
Prior art keywords
aav
methods
detection
determining
particles
Prior art date
Application number
CY20211100262T
Other languages
Greek (el)
English (en)
Inventor
Xiaoying Jin
Catherine R. O'riordan
Lin Liu
Kate ZHANG
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1124364T1 publication Critical patent/CY1124364T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20211100262T 2016-08-15 2021-03-24 Μεθοδοι για την ανιχνευση aav CY1124364T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
PCT/US2017/046814 WO2018035059A1 (en) 2016-08-15 2017-08-14 Methods for detecting aav

Publications (1)

Publication Number Publication Date
CY1124364T1 true CY1124364T1 (el) 2022-07-22

Family

ID=59762045

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100262T CY1124364T1 (el) 2016-08-15 2021-03-24 Μεθοδοι για την ανιχνευση aav

Country Status (23)

Country Link
US (5) US11698377B2 (https=)
EP (2) EP3851449A1 (https=)
JP (3) JP7021191B2 (https=)
KR (5) KR102538037B1 (https=)
CN (2) CN118688363A (https=)
AU (2) AU2017312951B2 (https=)
CA (1) CA3033856A1 (https=)
CL (2) CL2019000392A1 (https=)
CR (1) CR20190127A (https=)
CY (1) CY1124364T1 (https=)
DK (1) DK3497207T3 (https=)
ES (1) ES2863674T3 (https=)
HU (1) HUE053747T2 (https=)
IL (3) IL264819B2 (https=)
MA (1) MA55748A (https=)
MX (2) MX2019001938A (https=)
NZ (3) NZ791267A (https=)
PH (1) PH12019500316A1 (https=)
SG (2) SG11201901221YA (https=)
TN (1) TN2019000047A1 (https=)
TW (2) TWI781953B (https=)
WO (1) WO2018035059A1 (https=)
ZA (2) ZA201900945B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
NZ791267A (en) 2016-08-15 2025-11-28 Genzyme Corp Methods for detecting AAV
JP7455579B2 (ja) * 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
IL276859B2 (en) * 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
MX2020008932A (es) * 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
WO2019173434A1 (en) * 2018-03-06 2019-09-12 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US11391707B2 (en) * 2018-07-27 2022-07-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
EP3841109A4 (en) * 2018-08-21 2022-09-21 Massachusetts Eye and Ear Infirmary COMPOSITIONS AND METHODS TO MODULATE THE TRANSDUCTION EFFICIENCY OF ADENO-ASSOCIATED VIRUSES
US11345929B2 (en) * 2018-10-25 2022-05-31 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
HUE064411T2 (hu) * 2019-04-11 2024-03-28 Regenxbio Inc Méretkizárásos kromatográfiás módszerek rekombináns adeno-asszociált víruskészítmények jellemzésére
US11841352B2 (en) * 2019-07-31 2023-12-12 Thermo Finnigan Llc Determination and correction of retention time and mass/charge shifts in LC-MS experiments
CA3165911A1 (en) * 2020-01-03 2021-07-08 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
US20210261625A1 (en) 2020-01-29 2021-08-26 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
WO2022175728A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
EP4328292A1 (en) * 2021-04-20 2024-02-28 Universal Bio-Sampling Inc. Specimen retention card and specimen inspection method using same
TW202321691A (zh) * 2021-07-12 2023-06-01 美商再生元醫藥公司 用於分析病毒粒子之線上原生質譜方法
MX2024000133A (es) * 2021-07-12 2024-03-22 Regeneron Pharma Ensayo de cromatografía líquida para determinar la relación de la cápside de aav.
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
JPWO2023132338A1 (https=) * 2022-01-06 2023-07-13
US20250110119A1 (en) * 2023-03-03 2025-04-03 Sartorius Bioanalytical Instruments, Inc. Methods for quantitating viral capsids
US20240418730A1 (en) * 2023-06-19 2024-12-19 Regeneron Pharmaceuticals, Inc. Host cell protein analysis for adeno-associated virus (aav)-based gene therapy
US20250145969A1 (en) * 2023-11-08 2025-05-08 Oxford Biomedica (Us) Llc Deamidation Depleted Adeno-Associated Virus Product

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
WO2004027019A2 (en) 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
CA2503292A1 (en) * 2002-11-22 2004-06-10 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2311967B1 (en) * 2005-10-20 2017-09-20 UniQure IP B.V. Improved AAV vectors produced in insect cells
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010031865A1 (en) 2008-09-19 2010-03-25 Charitē Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
HUE028341T2 (en) 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
AU2013249202B2 (en) 2012-04-18 2018-08-09 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) * 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
NZ791267A (en) 2016-08-15 2025-11-28 Genzyme Corp Methods for detecting AAV

Also Published As

Publication number Publication date
EP3497207A1 (en) 2019-06-19
IL312792B1 (en) 2025-11-01
JP7021191B2 (ja) 2022-02-16
KR102738219B1 (ko) 2024-12-05
US20210041451A1 (en) 2021-02-11
KR20220107327A (ko) 2022-08-02
IL264819B1 (en) 2024-06-01
JP2024023460A (ja) 2024-02-21
EP3497207B1 (en) 2021-01-06
KR102425289B1 (ko) 2022-07-27
CN110168080B (zh) 2024-05-31
AU2017312951B2 (en) 2024-02-08
JP2019533803A (ja) 2019-11-21
CN118688363A (zh) 2024-09-24
IL312792A (en) 2024-07-01
CL2019002912A1 (es) 2020-03-06
ES2863674T3 (es) 2021-10-11
US20250138024A1 (en) 2025-05-01
AU2017312951A1 (en) 2019-04-04
KR20230078834A (ko) 2023-06-02
SG11201901221YA (en) 2019-03-28
IL312792B2 (en) 2026-03-01
NZ791263A (en) 2025-11-28
NZ751711A (en) 2025-11-28
ZA201900945B (en) 2021-06-30
BR112019002934A2 (pt) 2019-05-14
CN110168080A (zh) 2019-08-23
JP2022064980A (ja) 2022-04-26
MX2019001938A (es) 2019-07-04
RU2019107207A (ru) 2020-09-15
US11698377B2 (en) 2023-07-11
TW201825898A (zh) 2018-07-16
DK3497207T3 (da) 2021-03-22
CL2019000392A1 (es) 2019-05-10
TWI781953B (zh) 2022-11-01
CA3033856A1 (en) 2018-02-22
WO2018035059A9 (en) 2019-03-14
RU2019107207A3 (https=) 2021-04-29
KR20240172773A (ko) 2024-12-10
US20240044910A1 (en) 2024-02-08
NZ791267A (en) 2025-11-28
US20250147042A1 (en) 2025-05-08
IL264819A (https=) 2019-04-30
US20250027951A1 (en) 2025-01-23
SG10201913002QA (en) 2020-03-30
US12298313B1 (en) 2025-05-13
HUE053747T2 (hu) 2021-07-28
ZA202101002B (en) 2024-07-31
MX2023009081A (es) 2023-08-08
CR20190127A (es) 2019-06-25
WO2018035059A1 (en) 2018-02-22
AU2024200349A1 (en) 2024-02-08
IL323969A (en) 2025-12-01
EP3851449A1 (en) 2021-07-21
KR20260036296A (ko) 2026-03-16
TW202309068A (zh) 2023-03-01
PH12019500316A1 (en) 2019-08-05
KR102538037B1 (ko) 2023-05-30
MA55748A (fr) 2022-03-02
IL264819B2 (en) 2024-10-01
KR102922101B1 (ko) 2026-02-03
KR20190039253A (ko) 2019-04-10
TN2019000047A1 (en) 2020-07-15
US12123880B2 (en) 2024-10-22

Similar Documents

Publication Publication Date Title
CY1124364T1 (el) Μεθοδοι για την ανιχνευση aav
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
CY1124182T1 (el) Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου
CY1122520T1 (el) Συνθεσεις irna ιου ηπατιτιδας β (hbv) και μεθοδοι χρησης εξ αυτων
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CY1120489T1 (el) Εμβολια για hsv-2
CY1125387T1 (el) Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους
EP3790567A4 (en) LIVER-SPECIFIC TROPISM FROM ADENO-ASSOCIATED VIRUSES
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
EA201791630A1 (ru) Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
MX2022003681A (es) Caracterizacion de particulas virales de terapia genetica a traves del uso de cromatografia de exclusion de tama?os y las tecnologias de dispersion de la luz en multiples angulos.
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX383506B (es) Parvovirus porcino.
EP3347460A4 (en) MODIFIED ONCOLYTIC VACCINIA VIRUSES WITH CYTOKIN AND CAR-BOXY-REFERENCE EXPRESSION AND METHOD OF USE THEREOF
SG11201810014UA (en) Viral particle for rna transfer, especially into cells involved in immune response
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
SG11201810015YA (en) Particle for the encapsidation of a genome engineering system
MX378905B (es) Pestivirus.
GB201915905D0 (en) Viruses with modified capsid proteins
EA202191137A1 (ru) Способы анализа композиции вирусного капсидного белка
DK3387132T3 (da) Aptamerer, nukleinsyremolekyler, polynukleotider, syntetiske antistofsammensætninger til påvisning af prrs-vira og behandling af prrs-virusinfektion
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.